{"entity":{"id":"revolution-medicines","kind":"company","name":"Revolution Medicines","aka":["EQRx International, Inc.","EQRx"],"tldr":"Revolution Medicines is the leading RAS company, with daraxonrasib in phase 3 for pancreatic cancer.","summary":"Revolution Medicines, based in Redwood City, California, and listed as RVMD, is the leading RAS company, with daraxonrasib in phase 3 for pancreatic cancer. Its pipeline pairs daraxonrasib, a pan-RAS inhibitor, with elironrasib, selective for G12C in the active state, and zoldonrasib against G12D, tested in the RASolute and RASolve phase 3 programmes, and the company expanded its credit facility in 2025 to fund a launch. OnCo links it to pancreatic ductal adenocarcinoma, to the KRAS roadmap from undruggable through G12C to pan-RAS, to the bottleneck of undruggable drivers, and to the idea of covalent chemistry for RAS mutations that still have no drug. Whether pan-RAS inhibition is tolerable enough for long-term use is the open question. Daraxonrasib has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.revmed.com"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["daraxonrasib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07491445","nct07805954","nct07252232","nct07621718","nct06881784","nct07777822","nct06445062","nct07397338","nct05379985","nct06162221","nct06128551"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Redwood City, CA","country":"US","companyType":"biotech","website":"https://www.revmed.com","ticker":"RVMD","investors":[],"funding":[]},"route":"/companies/revolution-medicines/","neighbours":{"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"daraxonrasib","kind":"drug","name":"Daraxonrasib","route":"/drugs/daraxonrasib/"},{"id":"elironrasib","kind":"drug","name":"Elironrasib","route":"/drugs/elironrasib/"},{"id":"zoldonrasib","kind":"drug","name":"Zoldonrasib","route":"/drugs/zoldonrasib/"}],"trial":[{"id":"rasolute-302","kind":"trial","name":"RASolute 302","route":"/trials/rasolute-302/"},{"id":"nct06881784","kind":"trial","name":"Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)","route":"/trials/nct06881784/"},{"id":"nct07252232","kind":"trial","name":"Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)","route":"/trials/nct07252232/"},{"id":"nct07491445","kind":"trial","name":"Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","route":"/trials/nct07491445/"},{"id":"nct06128551","kind":"trial","name":"Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors","route":"/trials/nct06128551/"},{"id":"nct07777822","kind":"trial","name":"Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mu","route":"/trials/nct07777822/"},{"id":"nct07397338","kind":"trial","name":"Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors","route":"/trials/nct07397338/"},{"id":"nct06162221","kind":"trial","name":"Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC","route":"/trials/nct06162221/"},{"id":"nct06445062","kind":"trial","name":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","route":"/trials/nct06445062/"},{"id":"nct05379985","kind":"trial","name":"Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","route":"/trials/nct05379985/"},{"id":"nct06040541","kind":"trial","name":"Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors","route":"/trials/nct06040541/"},{"id":"nct07805954","kind":"trial","name":"Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut","route":"/trials/nct07805954/"},{"id":"nct07621718","kind":"trial","name":"Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-muta","route":"/trials/nct07621718/"}],"cancer":[{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/"},{"id":"kras-g12c-pdac","kind":"cancer","name":"KRAS G12C-mutant pancreatic ductal adenocarcinoma","route":"/cancers/kras-g12c-pdac/"},{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"paper":[{"id":"paper-holderfield-ras-on-multi-selective-inhibitor-nature-2024","kind":"paper","name":"Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy","route":"/key-papers/paper-holderfield-ras-on-multi-selective-inhibitor-nature-2024/"}],"roadmap":[{"id":"kras-roadmap","kind":"roadmap","name":"KRAS roadmap: undruggable → G12C → pan-RAS","route":"/roadmaps/kras-roadmap/"},{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/"}],"idea":[{"id":"idea-bio1-pan-ras-covalent-g12d","kind":"idea","name":"Covalent chemistry for the RAS mutations that still have no drug","route":"/ideas/idea-bio1-pan-ras-covalent-g12d/"},{"id":"idea-pdac-ras-inhibitor-combinations-and-sequencing","kind":"idea","name":"RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression","route":"/ideas/idea-pdac-ras-inhibitor-combinations-and-sequencing/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"}],"bottleneck":[{"id":"b-undruggable-targets","kind":"bottleneck","name":"The undruggable drivers","route":"/bottlenecks/b-undruggable-targets/"}],"company":[{"id":"bain-capital-life-sciences","kind":"company","name":"Bain Capital Life Sciences","route":"/companies/bain-capital-life-sciences/"},{"id":"boxer-capital","kind":"company","name":"Boxer Capital","route":"/companies/boxer-capital/"}]}}